Avalo Therapeutics (AVTX) Price & Analysis

Compare

1,030 Followers

AVTX Stock Chart & Stats

$15.05

-$0.55(-7.32%)

At close: Jan 08 4:00 PM EST

$15.05

-$0.55(-7.32%)

Day’s Range― - ―

52-Week Range$3.39 - $19.41

Previous CloseN/A

Volume10.82K

Average Volume (3M)456.91K

Market Cap

$216.36M

Enterprise ValueN/A

Total Cash (Recent Filing)$111.62M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.06

Next Earnings

Mar 26, 2026

EPS Estimate

-1.53

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.19

Shares Outstanding13,152,356

10 Day Avg. Volume297,553

30 Day Avg. Volume456,911

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.45

Price to Sales (P/S)136.95

P/FCF Ratio-1.23

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$37.00

Price Target Upside145.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enrolled.

Market OpportunityThe HS market is substantially underpenetrated, with only a small biologic market share, indicating a significant opportunity for an effective treatment like AVTX-009.

Strategic AdvantageAVTX-009 combines mechanistic precision with 15× higher affinity, a longer half-life, and greater bioavailability.

Bears Say

Clinical Development RisksRisks include potential delays in clinical development, negative clinical data, failure to achieve approval, slower-than-anticipated commercial uptake, and possible dilution risk.

Financial PerformanceAvalo recorded a 2Q25 net loss of $1.92 per share, which was higher than the estimated net loss of $1.23 per share.

Avalo Therapeutics News

Avalo Therapeutics reports Q3 EPS ($2.19), consensus ($1.64)

“Now that enrollment is complete, we’re fully focused on completing the LOTUS trial, preparing for the data readout...

2d ago

AVTX

Avalo Therapeutics completes enrollment in Phase 2 LOTUS trial

Avalo Therapeutics (AVTX) announced that the Company has completed enrollment in its Phase 2 LOTUS trial of AVTX-009...

10d ago

AVTX

Oppenheimer healthcare analysts hold an analyst/industry conference call

Analysts, along with Dr. Cole Claiborne discuss AVTX-009 in hidradenitis suppurativa (HS).on an Analyst/Industry conference call to be...

18d ago

AVTX

Avalo Therapeutics management to meet with Piper Sandler

Meetings to be held in Boston on October 14 and in New York on October 15 hosted by...

24d ago

AVTX

Avalo Therapeutics Reports Q3 2025 Financial Results

Avalo Therapeutics, Inc. ( ($AVTX) ) has released its Q3 earnings. Here is a breakdown of the information...

1d ago

AVTX

Avalo Completes Enrollment for Phase 2 LOTUS Trial

Avalo Therapeutics ( ($AVTX) ) has shared an update. On October 29, 2025, Avalo Therapeutics announced the completion...

10d ago

AVTX

Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study

Avalo Therapeutics, Inc. (($AVTX)) announced an update on their ongoing clinical study. Avalo Therapeutics, Inc. is conducting a...

12d ago

AVTX

Avalo Therapeutics Highlights AVTX-009 Potential in New Presentation

Avalo Therapeutics ( ($AVTX) ) has shared an update. On October 10, 2025, Avalo Therapeutics released an updated...

29d ago

AVTX

Avalo Therapeutics Strengthens Leadership with Key Appointments

An announcement from Avalo Therapeutics ( ($AVTX) ) is now available. On October 1, 2025, Avalo Therapeutics announced...

1M ago

AVTX

Avalo Therapeutics appoints Boyd as CBO, Ivanowicz as SVP, Human Resources

Avalo Therapeutics (AVTX) announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been...

1M ago

AVTX

Avalo Therapeutics Appoints Kevin Lind to Board

Avalo Therapeutics ( ($AVTX) ) has provided an update. On September 16, 2025, Avalo Therapeutics announced the appointment...

2M ago

AVTX

Avalo Therapeutics appoints Kevin Lind to board of directors

Avalo Therapeutics (AVTX) announced the appointment of Kevin Lind to its Board of Directors. He most recently served...

2M ago

AVTX

Avalo Therapeutics price target raised to $25 from $15 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Avalo Therapeutics (AVTX) to $25 from $15 and keeps a...

2M ago

ABBV

AVTX

Oppenheimer buyers of Avalo Therapeutics ahead of lutikizumab data

Oppenheimer recommends investors to be buyers of Avalo Therapeutics (AVTX) in anticipation of the presentation of lutikizumab’s open-label...

2M ago

AVTX

AVTX FAQ

What was Avalo Therapeutics’s price range in the past 12 months?

Avalo Therapeutics lowest stock price was $3.39 and its highest was $19.41 in the past 12 months.

What is Avalo Therapeutics’s market cap?

Avalo Therapeutics’s market cap is $216.36M.

When is Avalo Therapeutics’s upcoming earnings report date?

Avalo Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 138 days.

How were Avalo Therapeutics’s earnings last quarter?

Avalo Therapeutics released its earnings results on Nov 06, 2025. The company reported -$2.19 earnings per share for the quarter, missing the consensus estimate of -$1.658 by -$0.532.

Is Avalo Therapeutics overvalued?

According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Avalo Therapeutics pay dividends?

Avalo Therapeutics does not currently pay dividends.

What is Avalo Therapeutics’s EPS estimate?

Avalo Therapeutics’s EPS estimate is -1.53.

How many shares outstanding does Avalo Therapeutics have?

Avalo Therapeutics has 13,152,356 shares outstanding.

What happened to Avalo Therapeutics’s price movement after its last earnings report?

Avalo Therapeutics reported an EPS of -$2.19 in its last earnings report, missing expectations of -$1.658. Following the earnings report the stock price went down -6.261%.

Which hedge fund is a major shareholder of Avalo Therapeutics?

Currently, no hedge funds are holding shares in AVTX

Avalo Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-174.79%

Trailing 12-Months

Asset Growth

16.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Avalo Therapeutics

Avalo Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare and ultra-rare diseases. The company targets conditions with significant unmet medical needs, leveraging its proprietary platform to discover and develop novel treatments that improve patient outcomes. Avalo's core pipeline includes a range of product candidates designed to address genetic disorders and other serious health conditions, aiming to provide effective solutions for patients who have limited treatment options.

Avalo Therapeutics (AVTX) Earnings & Revenues

Historic Earnings Reports

AVTX Stock 12 Month Forecast

Average Price Target

$37.00

▲(145.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","26":"$26","49":"$49","14.5":"$14.5","37.5":"$37.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14.5,26,37.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.03,20.335384615384616,22.64076923076923,24.946153846153848,27.251538461538463,29.556923076923077,31.862307692307695,34.167692307692306,36.473076923076924,38.77846153846154,41.08384615384615,43.38923076923077,45.69461538461539,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.03,19.48923076923077,20.94846153846154,22.407692307692308,23.86692307692308,25.326153846153847,26.785384615384615,28.244615384615386,29.703846153846154,31.163076923076922,32.62230769230769,34.08153846153846,35.54076923076923,{"y":37,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.03,18.566153846153846,19.102307692307694,19.638461538461538,20.174615384615386,20.71076923076923,21.24692307692308,21.783076923076923,22.31923076923077,22.855384615384615,23.391538461538463,23.927692307692308,24.463846153846156,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.96,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.31,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >